Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 75

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 75
---
5 Plan, the shares underlying such awards will become available for issuance under the 2025 Plan. Neither awards that are assumed, substituted or exchanged under the 2025 Plan as a result of our acquisition of another company nor dividend equivalents will reduce the number of shares of stock available for grant under the 2025 Plan. Shares of stock issued pursuant to the 2025 Plan may be authorized but unissued shares or treasury shares.

Administration.The Board or a committee of the Board will administer the 2025 Plan, or the Board or a committee of the Board may delegate the authority to administer the 2025 Plan to an officer or other individual or group (the Board or a committee administering the 2025 Plan, or their delegate, if applicable, the “Administrator”). The Administratorhas discretion, subject to the terms of the 2025 Plan, to make all decisions relating to the 2025 Plan and outstanding awards.

Eligibility.Employees, outside directors and consultants are eligible to participate in our 2025 Plan. As of the Record Date, there were approximately 5 executive officers, 348 other employees eligible for awards and 9 eligible non-employee directors. The Administrator has the authority to select participants and determine the terms and conditions of awards granted to such participants. Terms of awards may vary among participants and among grants to the same participant.

Types of Awards.Our 2025 Plan provides for the following types of awards:

incentive stock options (“ISOs”) as described in Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), and nonstatutory stock options (“NSOs”), meaning stock options not described in Sections 422 or 423 of the Code;

SARs;

restricted shares;

RSUs; and

performance cash awards.

Options and SARs.The exercise price for options granted under the 2025 Plan may not be less than 100% of the fair market value of our common stock on the grant date; however, the exercise price for an ISO granted to a holder of more than 10% of the total combined voting power of all classes of our outstanding stock may not be less than 110% of such fair market value on the grant date in accordance with Section 422(c)(5) of the Code and Treasury Regulations Section 1.422-2(f). The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to ISOs that first become exercisable by an optionee during